LIDE is a Shanghai-based, translational medicine service provider, with 11 years of delivering innovations in oncology and immuno-oncology translational research. LIDE offers traditional pre-clinical CRO services like NGS, CR (conditionally reprogrammed) cell lines, organoid assays, in-vitro testing, etc and has a collection of more than 1700 patient derived xenograft (PDX) mouse models covering 40+ cancer types, of which 200+ are special drug resistant and/or genetically altered. LIDE also has proprietary, award-winning MiniPDX® and OncoVee® Kcell Assay Kit to offer 7-day, in-vivo drug sensitivity testing with results mirroring traditional PDX testing.
LIDE differentiates itself from other CROs by continually conducting self-funded internal research of its immense tumor bio bank, and working with KOLs in the academic space to vigorously promote the development and application of translational medical research. We also adopt the highest international operational standards. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment. We have 250+ clients across 2000+ projects.